FDA publishes complete response letter rejecting Summit's lung cancer drug
Published 3 h ago1 sourceEvidence: Reported
The FDA rejected Akeso's cancer drug ivonescimab, citing lack of substantial evidence of effectiveness, causing a 31.8% share price drop. This is a major setback for a leading Chinese innovative drug, raising doubts about its global commercial prospects and potentially impacting the broader Chinese biotech sector's sentiment.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 3 h ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported